Satellos Bioscience Inc. (MSLE)
| Market Cap | 141.43M +48.3% |
| Revenue (ttm) | n/a |
| Net Income | -39.96M |
| EPS | -2.09 |
| Shares Out | 21.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,722 |
| Open | 6.85 |
| Previous Close | 6.83 |
| Day's Range | 6.59 - 7.14 |
| 52-Week Range | 5.30 - 13.40 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 24.17 (+264.83%) |
| Earnings Date | Nov 12, 2026 |
About MSLE
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for MSLE stock is "Strong Buy." The 12-month stock price target is $24.17, which is an increase of 264.83% from the latest price.
News
Satellos reports Q3 EPS (53c), consensus (63c)
“Our progress in the second half of 2026 reflects continued execution across our programs and brings us closer to important clinical and regulatory milestones,” said Frank Gleeson, Satellos (MSLE) co-...
Satellos Bioscience Earnings release: Q3 2026
Satellos Bioscience released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Satellos Bioscience Report: Q3 2026
Satellos Bioscience published a report on November 12, 2026 containing material business information for investors and shareholders.
Satellos Bioscience MD&A: Q3 2026
Satellos Bioscience filed a regulatory document on November 12, 2026 disclosing important business information.
Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress
TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle dis...
Satellos Bioscience Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
FDA feedback led to fat fraction becoming BASECAMP’s primary endpoint, with data expected in Q1 2027. TRAILHEAD showed fat-fraction declines in its first four participants; funding extends through 2027, and NDA-enabling CMC work is underway.
Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results
Satellos Bioscience NASDAQ: MSLE said it will use MRI-measured muscle fat fraction as the primary efficacy endpoint in its Phase II BASECAMP study of forazapadin for boys living with Duchenne muscular...
Satellos Changes BASECAMP Endpoint After FDA Feedback; Data Expected In Q1 2027
(RTTNews) - Satellos Bioscience Inc. (MSLE) announced that, following feedback from the U.S. Food and Drug Administration (FDA), it has selected MRI-measured muscle fat fraction as the primary efficac...
Satellos Bioscience Transcript: Study update
BASECAMP will use 12-week MRI vastus lateralis fat-fraction change as its primary efficacy endpoint, following FDA discussion of a potential accelerated-approval path. Top-line data, including safety and available functional measures, are planned for Q1 2027.
Satellos Bioscience Press release: Study update
Satellos Bioscience issued a press release on November 6, 2026, disclosing material business information to investors.
Satellos Bioscience Slides: Study update
Satellos Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2026.
Satellos changes primary endpoint in BASECAMP trial after FDA feedback
Satellos (MSLE) announced that, following feedback from the FDA, it has selected change in vastus lateralis fat fraction measured by magnetic resonance imaging as the primary efficacy endpoint in the…
Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company developing potentially life-improving medicines to treat degenerat...
Satellos Bioscience Slides: Corporate presentation
Satellos Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2026.
Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
Company to host a conference call and audio webcast tomorrow at 8:00 a.m. ET Company to host a conference call and audio webcast tomorrow at 8:00 a.m. ET
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
Distinguished scientists bring expertise spanning stem cell biology, regenerative medicine, aging research, neuroscience and small molecule chemistry TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) — Satellos...
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
Distinguished scientists bring expertise spanning stem cell biology, regenerative medicine, aging research, neuroscience and small molecule chemistry Distinguished scientists bring expertise spanning ...
Satellos to Participate in Upcoming Investor Conferences
TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle dis...
Craig-Hallum initiates Satellos with a Buy ahead of BASECAMP data
As previously reported, Craig-Hallum initiated coverage of Satellos (MSLE) with a Buy rating and $24 price target The firm likes the setup ahead of Q1 2027 BASECAMP data, with shares…
Satellos initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Satellos (MSLE) with a Buy rating and $24 price target
Satellos Bioscience Slides: Corporate presentation
Satellos Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on October 8, 2026.
Satellos granted composition of matter patent for forazapadin
Satellos (MSLE) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled “AP2 associated kinase 1 inhibitors and uses thereof.” The patent includes ...
Satellos Granted Composition of Matter Patent for Forazapadin
Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, T...
Satellos Granted Composition of Matter Patent for Forazapadin
Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadi...
Satellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD
(RTTNews) - On Wednesday, Satellos Bioscience (MSLE) said it has completed enrollment in BASECAMP, a Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD...